About

A Clear Focus on Retinal and Refractive Eye Disorders

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders.

Targeting Front and Back of the Eye Indications

Our pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

APX3330

Our lead product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

APX3330 has been studied in over 340 patients across six Phase 1 and five Phase 2 trials.

Learn More About APX3330

Phentolamine Ophthalmic Solution 0.75% Eye Drops

Phentolamine Ophthalmic Solution 0.75% is being developed for several indications including pharmacologically-induced mydriasis, presbyopia, and dim light or night vision disturbances.

Phentolamine Ophthalmic Solution 0.75% is an investigational 505(b)(2) product candidate that has been studied in over 650 subjects across 12 completed Phase 1, 2, and 3 trials.

Learn More About Phentolamine Ophthalmic Solution 0.75%

Aligning Our Vision with Partners

As part of our strategy, we continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets.

Partnership Opportunities

Leadership in Drug Development

Our leadership team is comprised of seasoned professionals with decades of experience in the pharmaceutical, biotech and medical research industries. Meet our teams.